Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 7/2006

01-07-2006 | From the World Literature

Gerontology Forum

An Update on the Literature

Published in: Drugs & Aging | Issue 7/2006

Login to get access

Excerpt

  • Abstract
  • 1. Less Than Half of Patients Aged >55 Years with Diabetes Mellitus Receive ACE Inhibitors or Angiotensin Receptor Antagonists for the Prevention of Cardiovascular and Kidney Disorders
  • 2. Bimatoprost Best Value for Glaucoma in the US
  • 3. Bisphosphonates Fracture the Costs of Osteoporosis
  • 4. Flu Vaccine in Elderly Individuals: Intramuscular Versus Subcutaneous
  • 5. Alfuzosin Prevents Progression of Benign Prostatic Hyperplasia
  • 6. Long-Term Cost Effectiveness of α-Adrenoceptor Antagonists and Transurethral Resection of the Prostate Varies with Severity of Benign Prostatic Hyperplasia
  • 7. Naftopidil has Similar Efficacy to Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
  • 8. Treatment with NX 1207 for Benign Prostatic Hyperplasia May Provide Long-Term Efficacy
  • 9. Levocarnitine Helps Improve Symptoms of Physical and Mental Fatigue in the Elderly
  • 10. Telmisartan/Hydrochlorothiazide (HCTZ) Puts the Pressure on Lisinopril/HCTZ in the Elderly
  • 11. Ispronicline Promising for the Treatment of Memory Disorders
  • 12. Suboptimal Stroke Prevention in the Elderly with Atrial Fibrillation: Less Warfarin Use
  • 13. Donepezil Demonstrates Success Throughout the Alzheimer’s Disease Continuum
  • 14. Restful Legs Restored with Ropinirole
  • 15. Increased AWAREness with Donepezil Therapy for Alzheimer’s Disease
  • 16. Donepezil an Advantage in Severe Alzheimer’s Disease
  • 17. Leuprorelin Stabilises Cognition in Women with Alzheimer’s Disease
  • 18. Testosterone Therapy Improves Quality of Life in men with Alzheimer’s Disease
  • 19. New American Academy of Neurology Guidelines for Parkinson’s Disease
  • 20. Parkinson’s Disease: Treatment-Related Gambling and Compulsive Behaviours
  • 21. Parkinson’s Disease an Economic Burden on Patients and Society
  • 22. Pergolide Reduces Severity of Motor Complications in Parkinson’s Disease
  • 23. Initiating Rasagiline Worthwhile in Early Parkinson’s Disease
  • 24. Long-Term Rivastigmine Effective for Dementia Associated with Parkinson’s Disease
  • 25. The Selective Serotonin 5-HT2A Receptor Inverse Agonist ACP 103 May Be Beneficial for Parkinson’s Disease Patients with Treatment-Induced Psychosis
…
Footnotes
1
This study was supported by a grant from Allergan Inc., US, with which the researchers were affiliated.
 
2
The study was conducted from a healthcare payers’ perspective. Costs (year 2003 values) were those associated with study medications, adjunctive medications and physician visits.
 
3
One of the authors was affiliated with Eli Lilly Inc., Merck & Co., and Aventis.
 
4
Sponsored by Sanofi-Aventis.
 
5
Costs (2004 values) were reported from a US payer perspective and were those related to treatments and complications. Costs and benefits were discounted by 3% per annum.
 
6
Nymox Pharmaceutical Corporation, phase II for benign prostatic hyperplasia in the US.
 
7
Preceded by 2-week antihypertensive washout period.
 
8
Targacept, R.J. Reynolds Tobacco Company; phase II for cognition disorders in the US.
 
9
One of the authors had affiliations with Bristol-Myers Squibb and AstraZeneca.
 
10
Congestive heart failure, Hypertension, Age, Diabetes, Stroke.
 
11
Hepatic or renal disease, Ethanol abuse, Malignancy, Older age (>75 years), Reduced platelet count or function, Hypertension (uncontrolled), Anaemia, Genetic factors, Excessive fall risk, Stroke.
 
12
This study was supported by Eisai and Pfizer.
 
13
Patients randomised to the donepezil 10 mg/day group received donepezil 5 mg/day for the first 6 weeks of the study.
 
14
This study was supported by Pfizer.
 
15
Patients randomised to the donepezil 10 mg/day group received donepezil 5 mg/day for the first 30 days of the study.
 
16
This study was supported by GlaxoSmithKline.
 
17
Dosage increases were permitted after every 7 days up to a dosage of 2 mg/day, and every 14 days for dosages beyond this.
 
18
This study was funded by Pfizer, US, and Eisai, US.
 
19
This study was funded by Pfizer Pharmaceuticals, Sweden.
 
20
Voyager Pharmaceuticals; phase III for Alzheimer’s disease in Canada and the US.
 
21
The testosterone and placebo gels were supplied by Unimed Pharmaceuticals Inc.
 
22
The Judgment of Line Orientation, the Developmental Test of Visual-Motor Integration, and the Block Design Subtest of the Wechsler Adult Intelligence Scale-revised.
 
23
Costs (2002 values) were long-term care, inpatient and outpatient care, home healthcare, short-term facility and hospice care, and prescribed medication costs.
 
24
This study was sponsored by Eli Lilly.
 
25
The authors were affiliated with Lundbeck A/S, France.
 
26
This study was supported by Novartis Pharma, Switzerland.
 
27
ACADIA Pharmaceuticals; phase II for psychotic disorders and movement disorders in the US.
 
Literature
University of Michigan. More than half of older diabetics lack medicines that protect kidneys and heart, U-M study finds [media release]. 18 Apr 2006. University of Michigan [online]. Available from URL: http://​www.​med.​umich.​edu [Accessed 2006 May 20]
Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. PharmacoEconomics 2006; 24(3): 251–64PubMedCrossRef
Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99(2): 123–31PubMedCrossRef
Cook IF, Barr I, Hartel G, et al. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006; 24(13): 2395–402PubMedCrossRef
Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97(4): 734–41PubMedCrossRef
DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. PharmacoEconomics 2006; 24(2): 171–91PubMedCrossRef
Nishino Y, Masue T, Miwa K, et al. Comparison of two alpha-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006; 97(4): 747–51PubMedCrossRef
Nymox reports positive new efficacy data for benign prostatic hyperplasia drug [media release]. 16 May 2006. Hasbrouck Heights (NJ): Nymox Pharmaceutical Corporation [online]. Available from URL: http://​www.​nymox.​com [Accessed 2006 May 27]
Malaguarnera M, Di Mauro A, Gargante PM, et al. L-carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. South Med J 2006; 99(3): 315–6PubMedCrossRef
Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006; 20(3): 177–85PubMedCrossRef
Targacept announces positive phase II results for TC-1734 (AZD3480) in memory impaired older subjects [media release]. 17 May 2006. Targacept Inc. [online]. Available from URL: http://​www.​targacept.​com [Accessed 2006 May 27]
1.
Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006 Apr; 37(4): 1075–80PubMedCrossRef
2.
Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006 Apr; 37(4): 1070–4PubMedCrossRef
1.
Black S, Li H, McRae T, et al. Treatment of severe Alzheimer’s disease with donepezil: results from a 24-week, multinational, randomized, double-blind, placebo-controlled trial [abstract no. P06.057 plus poster]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): 347
2.
Winblad B, Eriksson S, Kilander L, et al. Efficacy of donepezil on secondary end points in a randomized, double-blind, placebo-controlled study in severe Alzheimer’s disease [abstract no. PO6.069 plus poster]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): 350
1.
Kushida CA, Tolson JM. Ropinirole is an effective treatment for patients with restless legs syndrome needing extended treatment coverage [abstract no. PO2.029 plus poster]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): 82
Johannsen P, Salmon E, Hampel H, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs 2006; 20(4): 311–25PubMedCrossRef
Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006 Apr 1; 367(9516): 1057–65PubMedCrossRef
Leuprolide acetate stabilizes cognitive and functional decline in women with Alzheimer’s disease, study shows [media release]. 16 May 2006. Voyager Pharmaceutical Corporation [online]. Available from URL: http://​www.​voyagerpharma.​com [Accessed 2006 May 27]
Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006; 63(2): 177–85PubMedCrossRef
New guidelines improve diagnosis for people with Parkinson disease [media release]. 28 Mar 2006. American Academy of Neurology [online]. Available from URL: http://​www.​aan.​com [Accessed 2006 Apr 29]
1.
American Academy of Neurology. Compulsive behaviors are common from Parkinson treatment [media release]. 24 Mar 2006. Newswire [online]. Available from URL: http://​www.​newswire.​com [Accessed 2006 Apr 29]
2.
American Academy of Neurology. Parkinson disease treatments show risk for developing gambling problems [media release]. 24 Mar 2006. Newswire [online]. Available from URL: http://​www.​newswire.​com [Accessed 2006 Apr 29]
Noyes K, Liu H, Li Y, et al. Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. Mov Disord 2006 Mar; 21(3): 362–72PubMedCrossRef
Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006 Mar; 21(3): 343–53PubMedCrossRef
Roch B, Eckert L, Guelfucci F, et al. A cost-effectiveness comparison of rasagiline with dopamine agonists for delaying levodopa use in early parkinsonian patients in the United Kingdom [abstract no. PNL3]. 2nd Asia-Pacific International Society for Pharmacoeconomics and Outcomes Research Conference; 2006 Mar 5; Shanghai [online]. Available from URL: http://​www.​ispor.​org [Accessed 2006 Apr 29]
Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 2006 Apr; 21(4): 456–61PubMedCrossRef
ACADIA Pharmaceuticals announces positive results from phase II trial of ACP-103 for treatment-induced psychosis in patients with Parkinson’s disease [media release]. 23 Mar 2006. ACADIA Pharmaceuticals Inc. [online]. Available from URL: http://​www.​acadiapharm.​com [Accessed 2006 Apr 1]
Metadata
Title
Gerontology Forum
An Update on the Literature
Publication date
01-07-2006
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200623070-00008

Other articles of this Issue 7/2006

Drugs & Aging 7/2006 Go to the issue

Original Research Article

Importance of Calcium Co-Medication in Bisphosphonate Therapy of Osteoporosis

Original Research Article

Therapeutic Failure-Related Hospitalisations in the Frail Elderly

Adis Drug Profile

Travoprost/Timolol

Original Research Article

Aspirin Resistance

Adis Drug Profile

Travoprost/Timolol

Therapy In Practice

Chronic Non-Infectious Uveitis in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits